Ophthalmic nepafenac use in the Netherlands and Denmark
- PMID: 28493461
- PMCID: PMC5518196
- DOI: 10.1111/aos.13468
Ophthalmic nepafenac use in the Netherlands and Denmark
Abstract
Purpose: To describe nepafenac use in the Netherlands and Denmark with reference to its approved indications. For context, we also describe the use of ketorolac and diclofenac.
Methods: We identified users in the PHARMO Database Network (the Netherlands, 2008-2013) and the Danish national health registers (Denmark, 1994-2014). We described prevalence of cataract surgery and duration of use in patients with cataract surgery with and without diabetes.
Results: In the Netherlands, 9530 nepafenac users (mean age, 71 years; 60% women) contributed 12 691 therapy episodes, of which 21% had a recently recorded cataract surgery. Of 2266 episodes in adult non-diabetic patients with cataract surgery, 60% had one bottle dispensed (treatment duration ≤21 days). Of 441 episodes in adult diabetic patients with cataract surgery, 90% had up to two bottles dispensed (≤60 days). Denmark had 60 403 nepafenac users (mean age, 72 years; 58% women) and 73 648 episodes (41% had recorded cataract surgery). Of 26 649 nepafenac episodes in adult non-diabetic patients with cataract surgery, 92% had one bottle dispensed. Of 3801 episodes in adult diabetic patients with cataract surgery, 99.8% had up to two bottles dispensed. Use patterns of nepafenac, ketorolac and diclofenac were roughly similar in the Netherlands, but not in Denmark.
Conclusion: Less than half of therapy episodes were related to cataract surgery; around 90% of episodes with surgery were within the approved duration. Underrecording of ophthalmic conditions and procedures was a challenge in this study.
Keywords: cataract; cataract surgery; diclofenac; ketorolac; nepafenac; off-label; ophthalmic NSAIDs.
© 2017 The Authors Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Figures


References
-
- Alcon (2015): Summary of product characteristics. Nevanac 1 mg/ml eye drops, suspension (nepafenac). Surry, UK: Alcon Laboratories (UK) Ltd; Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici.... (Accessed 22 Aug 2016).
-
- Allergan Pharmaceuticals Ireland (2014): Package leaflet: information for the user. Acular® 0.5% eye drops. Westport, Ireland: Allergan Pharmaceuticals Ireland; Acular® topical ophthalmic solution (ketorolac trometamol). Available at http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1423805271.... (Accessed 13 Jul 2016).
-
- Caldwell M & Reilly C (2008): Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. J Refract Surg 24: 377–382. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical